The role of the ALKBH5 RNA demethylase in invasive breast cancer
Authors:
- Corinne L. WoodcockCWCorinne L. Woodcock
- Mansour AlsaleemMAMansour Alsaleem
- Michael S. TossMTMichael S. Toss
- Jennifer Lothion-RoyJLJennifer Lothion-Roy
- Anna E. HarrisAHAnna E. Harris
- Jennie N. JeyapalanJJJennie N. Jeyapalan
- Nataliya BlattNBNataliya Blatt
- Albert A. RizvanovAlbert A. Rizvanov
- Regina R. MiftakhovaRMRegina R. Miftakhova
- Yousif A. KaririYKYousif A. Kariri
- Srinivasan MadhusudanSrinivasan Madhusudan
- Andrew R. GreenAndrew R. Green
Open Access
- 11 August 2024
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-17
Abstract
Background: N6-methyladenosine (m6A) is the most common internal RNA modification and is involved in regulation of RNA and protein expression. AlkB family member 5 (ALKBH5) is a m6A demethylase. Given the important role of m6A in biological mechanisms, m6A and its regulators, have been implicated in many disease processes, including cancer. However, the contribution of ALKBH5 to invasive breast cancer (BC) remains poorly understood. The aim of this study was to evaluate the clinicopathological value of ALKBH5 in BC. Methods: Publicly available data were used to investigate ALKBH5 mRNA alterations, prognostic significance, and association with clinical parameters at the genomic and transcriptomic level. Differentially expressed genes (DEGs) and enriched pathways with low or high ALKBH5 expression were investigated. Immunohistochemistry (IHC) was used to assess ALKBH5 protein expression in a large well-characterised BC series (n = 1327) to determine the clinical significance and association of ALKBH5 expression. Results: Reduced ALKBH5 mRNA expression was significantly associated with poor prognosis and unfavourable clinical parameters. ALKBH5 gene harboured few mutations and/or copy number alternations, but low ALKBH5 mRNA expression was seen. Patients with low ALKBH5 mRNA expression had a number of differentially expressed genes and enriched pathways, including the cytokine-cytokine receptor interaction pathway. Low ALKBH5 protein expression was significantly associated with unfavourable clinical parameters associated with tumour progression including larger tumour size and worse Nottingham Prognostic Index group. Conclusion: This study implicates ALKBH5 in BC and highlights the need for further functional studies to decipher the role of ALKBH5 and RNA m6A methylation in BC progression.Keywords
Funding Information
- BBSRC Doctoral Training Program ((BB/I024291/1))
- Kazan Federal University
- British Council ResearcherLinks program (RLWK10-458041157)
- University of Nottingham
This publication has 85 references indexed in Scilit:
- Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancerBreast Cancer Research and Treatment, 2019
- The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNABiochemical and Biophysical Research Communications, 2019
- Antipsychotic dopamine receptor antagonists, cancer, and cancer stem cellsArchives of Pharmacal Research, 2018
- HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7gCancer Letters, 2018
- RNA N6‐methyladenosine methyltransferase‐like 3 promotes liver cancer progression through YTHDF2‐dependent posttranscriptional silencing of SOCS2Hepatology, 2017
- m 6 A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation ProgramCancer Cell, 2017
- FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6 -Methyladenosine RNA DemethylaseCancer Cell, 2017
- N6-methyladenosine Modulates Messenger RNA Translation EfficiencyCell, 2015
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patientsBreast Cancer Research and Treatment, 2009
- High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysesInternational Journal of Cancer, 2005